For personal use only PRESENTATION FOR IMMEDIATE RELEASE 18 MARCH 2010 Pharmaceutical and Healthcare group, Stirling Products Limited (ASX:STI) is pleased to advise that following the settlement of its 4310 Sq Metre high-tech pharmaceutical production facility in Cape Breton, Canada and its highly successful launch of ‘Stirling Health’ at the Australian Pharmacy Professional Conference and Trade Exhibition (APP2010) last weekend, the Company will today commence a broker roadshow. The Presentation forms part of this Company Announcement and follows. In conjunction with the release of this Presentation the Company also advises of its new websites launched today which now better present the Company following the completion of the Company’s strategic acquisitions and product positioning. The Company’s major commercialisation drive is now conducted through five distinct business units. Sales and Manufacturing Divisions are a prime focus as will be the ongoing commercialisation works directed towards realising the three distinct blockbuster product opportunities that the Company has secured. For further information see www.stirlingproducts.net – www.stirlinghealth.com.au or contact: Peter Boonen Managing Director Stirling Products Limited Ph: +61 2 9299 9270 E: [email protected] For all Investor Relations inquiries please contact: James Moses Mandate Corporate Ph: +61 420 991 574 E: [email protected] For personal use only For personal use only Broker & Investment Presentation March 2010 For personal use only Forward Moving Statements This p presentation p provides only y an overview of Stirling g Products Limited ABN 32 077 105 429 (ASX:STI) and its opportunities. The information may require further explanation and/or clarification. Accordingly, this information should not be relied upon independently and should be considered in conjunction with past and future public information and announcements that are made by STI. Please contact STI and/or refer to the Company's website for further information. The views expressed in this presentation may contain information derived from publicly available sources that have not been independently verified. No representation or warranty is made as to the accuracy, completeness or reliability of the information. Any forward looking statements in this presentation have been prepared on a number of assumptions which may prove incorrect and the current intentions, plans, expectations and beliefs about future events are subject to risks, uncertainties and other factors, many of which are outside Stirling Products Limited’s control. These factors could cause actual results to differ materially from assumptions or expectations expressed or implied in this presentation. Because actual results may differ materially to assumptions made and STI’s current intentions, plans, expectations and beliefs about the future, you are urged to view all forward looking statements contained in this presentation with caution. caution Nothing in this presentation should be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in any jurisdiction. For personal use only About Stirling g Products Limited ASX:STI In only 12 months - we have built a global pharmaceutical and healthcare company Stirling g now: • has sales commencing across four divisions • owns a freehold high-tech $20M+ manufacturing plant in Canada • owns its future freehold 450 sq m Sydney office HQ • has a board with global senior industry experience and expertise • has h a tteam off world-class ld l managers & scientists i ti t • owns extensive IP and product range • owns JV interest in major drug delivery platform • has three serious blockbuster realization opportunities For personal use only 2010-2011 Full Year Positioned for Sales • ‘Stirling Pharma’ manufacturing base in Canada will concentrate initially on contract manufacturing - commencing Q2 • ‘Stirling Health’ Australian pharmacy brand launched in March 2010 • ‘Natures Firewall’ to be launched in Q2, 2010 as an Internet based brand • ‘i N t ‘i-Naturals’ l ’ to t be b llaunched h d iin Q4 Q4, 2010 as a N Network t kM Marketing k ti b brand d • positioned to achieve substantial and sustainable revenues Positioned for Blockbuster Realization For personal use only Corporate p – Our Board • Directors Peter Boonen Managing Director Neil Covey Director G lshan JJugroo Gulshan groo CFO/Director Professor Glyn Tonge Non Executive Director • The Company’s corporate headquarters are in Sydney, Australia • North American operations are based in Prince Edward Island, Canada • Manufacturing operations are based at Cape Breton, Canada • South African joint venture (Stanimate) based in Johannesburg For personal use only Scientific & Management Expertise Neil Covey – Extensive industry expertise. Former sales and marketing manager for Bayer Australia Prof Glyn Tonge – Extensive industry experience. Pharma, corporate finance, funds manager, funder, M&A, corporate and governance Michael Elliott – Extensive E tensi e National Sales Management e experience perience with ith Pfi Pfizer er and Innovex Dr Allen Bain – pharmacologist who co-developed a block buster antiarrhythmia drug now being commercialized by Merck Dr Aldar Bourinbaiar – specialist in viral disease, discovered an AIDS treatment used globally Dr Galyna Kutsyna – a researcher and specialist in AIDS and viral disease Dr Manuel Carpio – CEO Canada, Doctor of Veterinary Medicine Dr Hinner Koster – specialist in animal nutrition and health Dr Hugo Hattingh – specialist in animal nutrition and health For personal use only New Manufacturing g Facility y Stirling’s Stirling s 4,310sqm $20M+ $20M Pharmaceutical Plant For personal use only New Manufacturing g Facility y Stirling’s Stirling s 4,310sqm $20M+ $20M Pharmaceutical Plant laboratory For personal use only New Manufacturing g Facility y Within the current fit-out and configuration the plant has an annual capacity to manufacture and package over 550 million tablets, 5 million bottles and blend up to 1.5 1 5 million kg of product product. It also has a granulating and grinding capacity. For personal use only First Products to Market Stirling products being launched in markets include: Stirling Health – Pharmacy Sales A growing range of OTC, generic, health and beauty products, including products marketed for third parties Natural Health Products – Botanicals – ‘Nature’s Firewall’ & ‘i-Naturals’ a range of 26 unique products including: • ImmunoXel – for immune system optimization • Cholonorm – for cholesterol health • Diabetin – contains botanical extracts known to lower blood sugars • Allergon – for allergies Immunomodulator and/or adjuvant treatment • ImmunoXel – for all strains of TB, TB/HIV co-infection, AIDS and influenza For personal use only Products in Development p Stirling has three fully developed products having blockbuster – company making potential and which are the subject of ongoing commercialization works: • ImmunoXel – as an immunomodulator for treatment of AIDS, TB and flu • Inhalation Drug Delivery Platform – proven and patented platform technology that has demonstrated capability of improved delivery of many drugs through natural inhalation – this platform provides Stirling the potential and d opportunity t it off securing i marketshare k t h in i a range off blockbuster bl kb t d drugs as they come off patent • R-Salbutamol – world’s only single enantiomer beta agonist patented for human obesity – trial in beagle dogs demonstrated an approximate 2% per week weight loss For personal use only Drug g Delivery y Platform Key Features • Drug transport velocity - matched to the patient’s natural breathing • Reduced aerosol losses – less deposition on drug delivery pathways • Up to 3 times the aerosol concentration of other ultrasonic devices • Provides a concentration level between that currently achieved with dry powder inhalers and conventional fan driven nebulisers p • Delivered drugs – sub 5 micron - have much better & faster absorption • Active drug is in unique disposable capsules – competition protection • Testing has shown substantively LESS active drug (than oral) is needed to provide the same benefit – potential for increased safety and less side effects • Can potentially be used for administration of many major drugs For personal use only Products for Human Health Our p products and p pipeline p p products p provide for agents g that are effective in and/or beneficial for conditions including: • TB • AIDS • Obesity • Cholesterol • Diabetes • Allergies • Influenza • Generic Drug delivery Immunomodulators, such as ImmunoXel, can overcome bacterial drug resistance since they act through a totally new immune mechanism. Our botanical products are the first and only known products that can enhance the host’s defense against mycobacterial infections. Clinical trials have shown some of our products drastically shortened treatment duration and as an adjuvant contribute to curing certain conditions For personal use only Botanical Products Why a Focus on Botanicals? • The market for herbal and botanical products is forecast to grow by over 168% over the next 5 years to over US$33 billion • Over 60% of all New Chemical Entities for prescription pharmaceuticals in the last 5 years have been derived from natural or synthesized natural sources • There is a race on for the development of all natural immunomodulators For personal use only ImmunoXel Immunomodulator ImmunoXel has demonstrated in all its clinical trials that it: • • • • • • • • iis a powerful f l iimmunomodulator d l t and d adjuvant dj t substantively tunes the Immune System enhances efficacy of - antibiotics, viral therapies and chemotherapies can substantiallyy shorten drug g and chemotherapy py treatment duration can reduce and reverse treatment toxicity side-effects – esp. in liver and kidneys is market ready for treatment of TB, TB/HIV, AIDS over 800 patients treated in clinical trials – mainly TB, TB/HIV but also AIDS and influenza is a blockbuster product candidate For personal use only Proven in Tuberculosis ImmunoXel • Enhances efficacy of drugs 2-10 fold • Shortens therapy duration 3-12 fold • Reduces R d and d reverses ttoxicity i it off current TB drugs • Is market ready for TB and TB/HIV treatment • Over 800 patients treated in clinical trials to date “…a drug effective against drug resistant TB can earn US$300 million a year…” y - Global TB Alliance For personal use only Proven in AIDS Trials ImmunoXel In clinical trials when ImmunoXel was used as an adjuvant to anti-retroviral (ART) chemotherapy in the treatment of AIDS patients and compared to patients only on ART - ImmunoXel: I X l • • • • • • • • • Significantly increased CD3 T-lymphocytes CD 4 T cellll population CD-4 l ti almost l td doubled bl d The CD-4/CD-8 ratio increased 29.7% CD-20 and B-lymphocytes declined to normal levels of around 333 CD-3, HLA-DR and T-cell p population p increased 216% The CD3, CD16, CD56 and natural killer cells increased by 52.7% 95% of all patients had decrease in viral load burden Reduced and reversed toxicity side effects of ART Is market ready for use as an AIDS ART adjuvant treatment Over 35 million people are living with HIV/AIDS today For personal use only Botanical Products BOTANICAL PRODUCTS AS DIETARY SUPPLEMENTS Stirling has joint ventured the exclusive global marketing rights to a range of 26 botanical products that until now have only been sold through health care professionals in limited parts of Europe Each product has potential health benefits and has been tested and proven through extensive clinical trials in major academic and research institutions and also proven through their extensive use in Eastern Europe Condition Allergies Anemia Arthritis Sore muscles Asthma Cholesterol Heart health Hypertension Diabetes and obesity Immune system Immune system – preventative Hormonal imbalance in women Allergy and autoimmune diseases Muscle support Kidney diseases Neurological diseases Gastritis, stomach ulcer Ch i pancreatitis Chronic titi & iindigestion di ti Chronic prostatitis Varicose veins Indigestion Rheumatism, arthritis Thyroid gland dysfunction Hepatitis Endocrine disorders Psycho-emotional stress Product ALLERGIL ANEMIN ARTROSAN ARTROSAN-SPORT BRONCHIN CHOLENORM CORDEVIT CRYSTAL DIABETIN IMMUNOXEL IMMUNOXEL-P FЕМINAL LIZORM MYOTROP NEPHROPATHIN NEURIN NORK PANCREN PREDZAREN PROVEN RENORM RHEUMOSAN SCHIZAREN SVITANOK TROPONORM ZSP For personal use only Development p ST-810 ST 810 for Obestity ST- 810 is fully developed, chirally (molecular) pure, and has been safely used by humans for respiratory disease (asthma) for over 15 years in its purified form and 30 years in its original formulation formulation. Stirling is re-purposing this “old drug” for a “new use” - a well established product development process within the pharmaceutical industry. ST- 810 is a “metabolic switch” that turns off the body’s fat production receptors and then lets the body naturally adjust its weight. To commercialize the ST- 810 product, the Company intends to partner with a major pharmaceutical group For personal use only Major j Opportunity pp y Obesity In Australia - the total cost of obesity in 2008 was $58.2 billion which included the attributable cost of diseases such as diabetes, cardiovascular disease, various types of cancer and osteoarthritis. - Weighing it Up: Obesity in Australia May 2009 • House of Representatives Standing Committee Report on Health and Ageing In USA - “It's no secret that Americans are fat… Nearly one-third of U.S. adults are overweight, and another third are technically obese, as defined by y a BMI (body-mass ( y index)) of more than 30. 30 And Americans aren't happy about it. Last year, they spent an estimated $46 Billion on diet products.” - Forbes F b Magazine M i For personal use only Commercialization Stirling g Process Strategy gy • ‘Stirling Pharma’ starts manufacturing in Q2 • Launch of ‘Stirling Health’ – sales to pharmacies commence April Q2 • Launch L h off ‘Nature’s ‘N t ’ Firewall’ Fi ll’ – Internet I t t sales l network t k based b d in i Canada C d tto launch in Q2 • Launch of ‘i-Naturals’ – USA based network marketing health, beauty and anti aging prod anti-aging products cts to la launch nch in Q4 or Q1 Q1, 2011 • Joint venturing of products and/or technologies - ongoing • Licensing of products, in and out - ongoing • Relationship establishment with governments and continued clinical trials in areas of unmet need such as TB and HIV throughout the Africa – ongoing • Development of pre-production pre production inhalation platform devices - ongoing For personal use only Our Future Underpinned by Tangible Assets • • $20M+ replacement value - near new, freehold pharmaceutical plant Freehold offices – est. value $2.5 million …. positioned for: • significant sales revenues – commencing early Q2 • realization of major blockbuster potential opportunities - ImmunoXel as a treatment adjunct for AIDS and TB - inhalation drug delivery platform - obesity drug candidate • jjoint ventures with major j p pharmas • continued aggressive growth .... to realize: • market awareness • re-assessment as an investment opportunity! For personal use only Summary y Our position is unique. We are positioned as a manufacturer and marketer of pharmaceutical, generic and healthcare products In a very short 12 month time-frame we have now launched two of our four sales initiatives in ‘Stirling Pharma’ and ‘Stirling Health’ and also established our unique advantage in that most of our products are: • fully developed • market ready Additionally we have serious potential blockbuster opportunity in: Additionally, • ImmunoXel with demonstrated unmatched performance in trials for the treatment of TB and AIDS • a fully developed Drug Delivery Platform with unprecedented potential • the IP for a future obesity drug and: • our growth th continues.... ti For personal use only Th k you Thank Please visit: stirlingproducts.net